We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Below we will list the departments and units that form part of Vall d’Hebron Hospital and the main diseases that we treat. We will also make recommendations based on advice backed up by scientific evidence that has been shown to be effective in guaranteeing well-being and quality of life.
We will guide you from your first visit to the centre, allowing you to find all the departments and make the most of our facilities. Whatever the reason for your visit, we will explain how to get about the hospital.
Speaker: Dr. Joaquin Seras, Group: Drug Delivery and Targeting
I performed my PhD at the Autonomous University of Barcelona (UAB, 2012). There, I focused on the development of first-in-class biomedical uses for bacterial Inclusion Bodies (IBs). IBs are recombinant protein deposits, between the nano- and micro scale, historically discarded as waste by products of protein production. My research studied the IB-exerted stimuli on mammalian cell interfaces when producing complex nanotopographies for tissue engineering. After my PhD I devoted myself to expand the catalogue of biomedical uses for IBs, as high added value biomaterials. I engineered IBs to be used as depots for the slow release of therapeutic proteins, polyvalent coatings and immunomodulatory particles.
I moved to Vall d'Hebron Research Institute (VHIR) in 2015 awarded with an AECC post-doctoral fellowship. Here, I have continued my work in the nano-sphere. Particularly, I have participated in the development of Polymeric Micelles (PM) for the PM-mediated intracellular delivery of therapeutic antibodies, targeting cancer stem cell intrinsic drug resistance. In parallel, I started to explore the potential of extracellular vesicles (EVs). First, as central mediators of intercellular communication with roles in cancer cell plasticity regulation and premetastatic niche conditioning. Secondly, exploiting EVs capacity as protein delivery systems. In this regard, I focused on the generation of protein therapeutics loaded in vivo into EVs. This approach combines protein production and NP functionalization in a single step with intended applications in rare diseases and cancer therapy.
Host: Dra. Ibane Abasolo, The Drug Delivery and Targeting (DDT) group
Vall d’Hebron Research Institute
Children's Hospital and Woman's Hospital
Person in charge/Manager/Director,
Vall d’Hebron Research Institute
Select the newsletter you want to receive:
By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to email@example.com, clearly stating the subject as "Exercising of Data Protection Rights".
Operated by: Hospital Universitari Vall d'Hebron - Institut Català de la Salut.
Purpose: Manage the user’s contact information.
Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use.
Source: The interested party themselves.